China Shineway Pharmaceutical GroupCSWYY 92 Return-on-Tangible-Equity is 8.73% as of Dec. 2025, which is 19% below its 10-year median of 10.77. GuruFocus rates CSWYY with a GF Score™ of 92/100 and a GF Value™ of $17.28. The stock has 2 warning signs investors should review. Among 896 Drug Manufacturers companies, China Shineway Pharmaceutical Group ranks better than 64.96% on this metric.
The historical rank and industry rank for China Shineway Pharmaceutical Group's Return-on-Tangible-Equity or its related term are showing as below:
CSWYY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 5.52 Med: 10.77 Max: 14.76
Current: 12.6
During the past 13 years, China Shineway Pharmaceutical Group's highest Return-on-Tangible-Equity was 14.76%. The lowest was 5.52%. And the median was 10.77%.
CSWYY's Return-on-Tangible-Equity is ranked better than 64.96% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs CSWYY: 12.60
China Shineway Pharmaceutical Group (OTCPK:CSWYY) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
China Shineway Pharmaceutical Group Return-on-Tangible-Equity Related Terms
China Shineway Pharmaceutical Group Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Shineway Pharmaceutical Group Return-on-Tangible-Equity Chart
CSWYY vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Shineway Pharmaceutical Group's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Shineway Pharmaceutical Group Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Shineway Pharmaceutical Group's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where China Shineway Pharmaceutical Group's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 8.73% mean?
China Shineway Pharmaceutical Group (CSWYY) has a Return-on-Tangible-Equity of 8.73% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Shineway Pharmaceutical Group and its competitors. This is 19% below median its historical median of 10.77. Over the past decade, China Shineway Pharmaceutical Group's Return-on-Tangible-Equity has ranged from 5.52 to 14.76. According to the industry distribution chart, China Shineway Pharmaceutical Group ranks #314 out of 896 companies in the Drug Manufacturers industry, placing it in the top 35%.
Is China Shineway Pharmaceutical Group's Return-on-Tangible-Equity too high?
China Shineway Pharmaceutical Group's current Return-on-Tangible-Equity of 8.73% is 19% below median its 10-year median of 10.77. Over the past 10 years, this metric has ranged from a low of 5.52 to a high of 14.76. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. China Shineway Pharmaceutical Group's value of 8.73% is 12% above this industry median. Based on the distribution chart, China Shineway Pharmaceutical Group ranks #314 out of 896 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Shineway Pharmaceutical Group has a GF Score™ of 92/100, reflecting its overall financial health beyond just this single metric.
How does China Shineway Pharmaceutical Group's Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Shineway Pharmaceutical Group ranks #314 out of 896 companies for Return-on-Tangible-Equity. This puts China Shineway Pharmaceutical Group in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.80. China Shineway Pharmaceutical Group's value of 8.73% is 12% above this benchmark. Historically, China Shineway Pharmaceutical Group's own Return-on-Tangible-Equity has ranged from 5.52 to 14.76 over the past decade. While the company's 10-year median is 10.77 vs. the industry median of 7.80, China Shineway Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Shineway Pharmaceutical Group's current Return-on-Tangible-Equity of 8.73% is 12% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on China Shineway Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Shineway Pharmaceutical Group's current Return-on-Tangible-Equity is 8.73%, which is 19% below median its own 10-year median of 10.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Shineway Pharmaceutical Group stock overvalued right now?
China Shineway Pharmaceutical Group (CSWYY) has a current Return-on-Tangible-Equity of 8.73%. The stock's GF Value™ is $17.28, compared to a current price of $19.25 — trading 11.4% above its estimated fair value. The current Return-on-Tangible-Equity is 8.73%, which is 19% below median its 10-year median of 10.77 and 12% above the Drug Manufacturers industry median of 7.80. China Shineway Pharmaceutical Group's overall GF Score™ is 92/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For China Shineway Pharmaceutical Group (CSWYY), the current Return-on-Tangible-Equity is 8.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Shineway Pharmaceutical Group (CSWYY) Overvalued in 2026?
Based on GuruFocus' analysis, China Shineway Pharmaceutical Group stock appears to be overvalued.
The current stock price of $19.25 is trading 11.4% above its estimated GF Value™ of $17.28.
Key valuation signals for CSWYY:
Return-on-Tangible-Equity: 8.73% (19% below median its 10-year median of 10.77)
GF Value™: $17.28 vs. price of $19.25 (11.4% above fair value)
Industry Position: 12% above the Drug Manufacturers median (#314 of 896)
No single metric tells the full story. See the CSWYY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Shineway Pharmaceutical Group Business Description
China Shineway Pharmaceutical Group Ltd is an investment holding company. Along with its subsidiaries, it is engaged in the research, development, manufacturing, and trading of modern Chinese medicines. The company's products comprise injection, soft capsule, granule, traditional Chinese medicine formula granules, and others, of which injections generate maximum revenue for the company. Geographically, the group operates in the People's Republic of China (PRC) and Hong Kong.
92GF Score
Get the complete analysis for CSWYY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSWYY has been successfully added to your 
